Skip to main content
OPTUS Pharmaceutical Co., Ltd. logo

OPTUS Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 131030 ISIN · KR7131030009 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2025-03-10 Proxy Solicitation & In…
Country KR South Korea
Listing KO 131030

About OPTUS Pharmaceutical Co., Ltd.

http://optuspharm.com/us/main/index.php

OPTUS Pharmaceutical Co., Ltd. is a specialized pharmaceutical company focused on the research, development, manufacturing, and commercialization of ophthalmic products. The company's primary expertise lies in producing sterile, preservative-free, single-dose (unit-dose) formulations. Its therapeutic portfolio addresses conditions such as dry eye syndrome, keratoconjunctival epithelial disease, bacterial conjunctivitis, and glaucoma. In addition to prescription and over-the-counter pharmaceuticals, the company is expanding into a total eye care model through its OUE& brand, which encompasses nutritional supplements (OUEFIT) and cosmeceuticals (OUELAB). The company operates EU-GMP certified manufacturing facilities and distributes its products globally.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Optus Pharm Co., Ltd. It includes the meeting agenda, financial statements, director candidate information, and governance details. This document is a formal proxy statement and meeting notice provided to shareholders, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-10 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It includes details on the meeting agenda, director nominations, and financial statements. This falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Optus Pharm. It details the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and appointment of audit committee members. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2025-03-07 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Optus Pharm Co., Ltd. It details the meeting date, location, agenda items (such as financial statement approval and director appointments), and provides management reference materials including business overviews and financial statements. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their participation/votes. In the context of the provided categories, this fits best as a Proxy Solicitation & Information Statement.
2025-03-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding the upcoming Annual General Meeting (AGM), including agenda items (approval of financial statements, election of directors), proxy solicitation details, and voting procedures. This document is a formal proxy statement sent to shareholders to solicit votes for the meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-07 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of the CEO (Representative Director) of Optus Pharm. It details the outgoing and incoming directors, the reason for the change, the date of the board resolution, and the professional background of the new appointee. This falls directly under the category of Board/Management Information (MANG).
2025-02-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.